Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Efficacy and safety of apaluta...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Efficacy and safety of apalutamide with high-volume mHSPC: Real-world experience from three cases

Efficacy and safety of apalutamide with high-volume mHSPC: Real-world experience from three cases

Bibliographic Details
Main Authors: Jingqi Jiang, Hui Ding, Panfeng Shang, Zhiping Wang
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:Asian Journal of Surgery
Subjects:
Metastatic hormone-sensitive prostate cancer
High-volume
ADT
Apalutamide
Prostate-specific antigen
Online Access:http://www.sciencedirect.com/science/article/pii/S101595842300461X
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S101595842300461X

Similar Items

  • Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report
    by: Zhiquan Hu, et al.
    Published: (2022-05-01)
  • Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database
    by: Mario Hassi Roman, et al.
    Published: (2024-12-01)
  • Apalutamide for prostate cancer: Multicentre and multidisciplinary real‐world study of 227 patients
    by: Julián Córdoba Sánchez, et al.
    Published: (2023-12-01)
  • Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial
    by: Dingyuan Yang, et al.
    Published: (2023-11-01)
  • Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    by: Qi Wang, et al.
    Published: (2025-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs